Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lurtotecan SCHEMBL13992 | 1.00 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL19208 | 1.00 | TOP1 (1.00) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL1649335 | 0.99 | TOP1 (0.98) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL29379042 | 0.99 | TOP1 (0.98) | TOP1SLC2A1 | |
| Lurtotecan SCHEMBL1649336 | 0.98 | TOP1 (0.97) | TOP1SLC2A1 | |
| SCHEMBL31312371 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21410041 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL21450469 | 0.95 | TOP1 (1.00) | TOP1SLC2A1 | |
| SCHEMBL15150090 | 0.93 | TOP1 (0.87) | TOP1SLC2A1 | |
| SCHEMBL17057475 | 0.92 | TOP1 (0.86) | TOP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716554-A1 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | Allygen Group (KY) | 2026-04-01 | — | — | EP | disclosed |
| WO-2024240162-A9 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024240162-A1 | PD-L1 AND TROP-2 TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2024-11-28 | — | — | WO | disclosed |
| US-20240299576-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | ALLYGEN GROUP (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240189442-A1 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | ALLYGEN GROUP (KY) | 2024-06-13 | — | — | US | disclosed |
| EP-4297798-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | Allygen Group (KY) | 2024-01-03 | — | — | EP | disclosed |
| EP-4297791-A1 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | Allygen Group (KY) | 2024-01-03 | — | — | EP | disclosed |
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | NEOPHARMA JAPAN CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| CN-115768415-A | Novel therapeutic and/or prophylactic agent for coronavirus infection (COVID-19) | 日本纽翱医药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4140479-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | Neopharma Japan Co., Ltd. (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-20220395497-A1 | Cancer Treatment Using Camptothecin Derivatives | VIVACITAS ONCOLOGY, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11467158-B2 | BRCA1 mutations as predictive markers for topoisomerase inhibitions | BOSTON MEDICAL CENTER CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| WO-2022205316-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022178754-A1 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022179571-A1 | TARGETING CONJUGATES COMPRISING TARGETING MOIETY BINDING FRAGMENTS AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022178753-A1 | TARGETING CONJUGATES COMPRISING TARGETING MOIETY BINDING FRAGMENTS AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022179572-A1 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022178751-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022179570-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | SHANGHAI ALLYGEN BIOLOGICS CO., LTD. (CN) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433136-B2 | Polyacetal polymers, conjugates, particles and uses thereof | CD44, FUT6, MSN | TOP1 1036/4885SLC2A1 1035/4885 |
| US-20240189442-A1 | TARGETING CONJUGATES WITH THERAPEUTIC AGENTS AND OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, TERF2, PAICS | TOP1 97/4885SLC2A1 2983/4885 |
| US-20230190690-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENT FOR CORONAVIRUS DISEASE 2019 (COVID-19) | ACE, ACE2, IL5 | TOP1 4066/4885SLC2A1 1498/4885 |
| US-20240299576-A1 | TARGETING CONJUGATES COMPRISING EFFECTOR MOLECULES AND USES THEREOF | GZMB, KLK3, CD47 | TOP1 2572/4885SLC2A1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.